Pharmacokinetics and electrocardiographic effects of a new controlled‐release form of flecainide acetate: Comparison with the standard form and influence of the CYP2D6 polymorphism

Abstract

Flecainide-induced QRS prolongation did not differ between the new controlled-release form and the immediate-release form. Flecainide plasma concentrations associated with the new controlled-release form predicted QRS prolongation with less variability compared with the immediate-release form. The CYP2D6 polymorphism did not appear to influence flecainide disposition kinetics or electrocardiographic effects at steady state.